ST. PAUL, Minn.–(BUSINESS WIRE)–Minnetronix Medical, a leading medical technology company, announces appointment of Jeremy Maniak to President and CEO.
Author: Business Wire
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
DUBLIN–(BUSINESS WIRE)–Horizon announced that clinical data for teprotumumab in the treatment of active thyroid eye disease will be presented at the ACR Annual Meeting.
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of…
NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures
EMERYVILLE, Calif.–(BUSINESS WIRE)– #NovaBay–NovaBay Pharmaceuticals launches online sales of CelleRx skin cleanser for post-aesthetic dermatology and cosmetic procedures
Global Optical Microscope Markets, 2016-2019 & Forecast to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Microscope Market to 2027 – Global Analysis and Forecasts By Product, By End User, and Geography” report has been added to ResearchAndMarkets.com’s offering. The global optical microscope market is expected to reac…
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
DUBLIN–(BUSINESS WIRE)–Horizon announced that integrated data for teprotumumab for the treatment of active thyroid eye disease (TED) were presented at the ATA Annual Meeting
Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial resu…
Resumen: La EMA y la FDA aceptan solicitudes de comercialización para satralizumab de Chugai en el trastorno del espectro de la neuromielitis óptica (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado que la Agencia Europea de Medicamentos (EMA) ha aceptado la solicitud de autorización de comercialización para satralizumab (código de desarrollo: SA237), un receptor an…
Samenvatting: EMA en FDA accepteren marketingtoepassingen voor Chugai’s Satralizumab bij Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde aan dat het Europees Geneesmiddelenbureau (EMA) de aanvraag voor een vergunning voor het in de handel brengen van satralizumab (ontwikkelingscode: SA237), een anti-interleuk…
EMA和FDA受理中外製藥用於泛視神經脊髓炎(NMOSD)的satralizumab的行銷申請
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)宣布，歐洲藥品管理局(EMA)已受理satralizumab（開發代碼：SA237）的行銷授權申請，該藥是一種抗白介素6 (IL-6)受體人化回收型抗體，用於治療成人和青少年泛視神經脊髓炎(NMOSD)患者。EMA已授予satralizumab加速評估(Accelerated Assessment)狀態。美國食品藥品管理局(FDA)…
EMA und FDA nehmen Zulassungsanträge für Satralizumab gegen Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) von Chugai entgegen
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), hat bekannt gegeben, dass die Europäische Arzneimittel-Agentur (EMA) den Zulassungsantrag für Satralizumab (Entwicklungscode: SA237), einen humanisierten, rezyklierenden Interleukin…
L'EMA et la FDA acceptent les demandes de mise sur le marché du satralizumab de Chugai pour la maladie du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que l’Agence européenne des médicaments (EMA) a accepté la demande d’autorisation de mise sur le marché du satralizumab, (code de développement : SA237), un anticorps de r…
Glaukos Announces Participation in Stephens Investor Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical methods trial of to…
Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program
CRANBURY, N.J.–(BUSINESS WIRE)– #AAO2019–Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program
Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
HTL investit dans des capacités de production GMP pour soutenir un marché des applications médicales de l’Acide Hyaluronique en forte croissance.
JAVENÉ, France–(BUSINESS WIRE)–HTL, leader mondial de la production d’Acide Hyaluronique et d’autres biopolymères, annonce qu’il investit dans une unité de production à la pointe de la technologie, qui multipliera par 2,5 sa capacité de production de…